Clin Mol Hepatol.
2025 Apr;31(2):669-670. 10.3350/cmh.2024.0333e.
Erratum to ‘Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial’ [Clin Mol Hepatol 2024;30:807-823]
- Yim SY1
- Lee SH2
- Baek SW3
- Sohn B4
- Jeong YS4
- Kang SH5
- Park K6,7
- Park H4
- Lee SS8
- Kaseb AO8
- Park YN9
- Leem SH10,11
- Curran MA12
- Kim JH1
- Lee JS
4
- Affiliations
-
- 1Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea
- 2Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, CHA Bundang Medical Center, CHA University, Seongnam, Korea
- 3Metabolic Regulation Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon, Korea
- 4Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
- 5Department of Surgery, Korea University Guro Hospital, Seoul, Korea
- 6Department of Obstetrics and Gynecology, Kyung Hee University Hospital at Gangdong, Seoul, Korea
- 7Department of Medicine, Graduate School, Kyung Hee University, Seoul, Korea
- 8Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
- 9Department of Pathology, Yonsei University College of Medicine, Seoul, Korea
- 10Department of Biomedical Sciences, Dong-A University, Busan, Korea
- 11Department of Health Sciences, The Graduate School of Dong-A University, Busan, Korea
- 12Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
- KMID: 2567001
- DOI: http://doi.org/10.3350/cmh.2024.0333e
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Transcriptomic signature in advanced hepatocellular carcinoma tissue to predict combination immunotherapy response: Editorial on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial”
- Personalized approaches to the treatment of hepatocellular carcinoma using immune checkpoint inhibitors: Editorial on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial”
- Reply to correspondence on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial”
- Correspondence to editorial 1 on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: insights from the IMbrave150 Trial”
- Correspondence to letter to the editor on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial”
